Insider Transactions in Q3 2023 at Intra Cellular Therapies, Inc. (ITCI)
Insider Transaction List (Q3 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2023
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
105
+1.09%
|
$5,460
$52.09 P/Share
|
|
Sep 30
2023
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
345
+0.43%
|
$17,940
$52.09 P/Share
|
|
Sep 19
2023
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
44,413
-4.06%
|
$2,398,302
$54.17 P/Share
|
|
Sep 18
2023
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
55,587
-2.45%
|
$2,946,111
$53.75 P/Share
|
|
Aug 07
2023
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
55,300
-54.95%
|
$3,207,400
$58.79 P/Share
|
|
Aug 07
2023
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
55,300
+35.46%
|
$995,400
$18.59 P/Share
|
|
Jul 17
2023
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,842
-7.97%
|
$119,730
$65.0 P/Share
|